A newly developed hepatitis C virus screening assay, Elecsys anti-HCV Ⅱ assay: performance evaluation and comparison with other widely used assays
Yang Ruifeng,Guan Wenli,Wang Qian,Liu Yan,Wei Lai
Peking University People′s Hospital, Peking University Hepatology Institute,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing 100044,China
Abstract：Background The persistence of hepatitis C virus (HCV) infection remains as a major cause of liver cirrhosis and hepatocellular carcinoma. HCV infection is often asymptomatic, thus diagnosis relies heavily on clinical laboratory assays. As an “indirect” test, the anti-HCV screening assay fails to detect HCV infection in the seroconversion window and might report false-negative Results in severely immunosuppressed populations.However,it is cheaper,simpler, and can provide Results more rapidly. Therefore it remains the preferred method for screening HCV infection in most clinical laboratories.As a newly developed anti-HCV screening assay, the Elecsys anti-HCV Ⅱ assay has been recently launched. Objective To evaluate Elesys anti-HCV Ⅱ assay performance in Chinese populations and compare it with other widely used anti-HCV screening Methods .Methods Four HCV seroconversion panels, 861 fresh consecutive serum samples under routine clinical conditions,100 preselected serum samples with low positive anti-HCV Results (tested before using the Vitros anti-HCV assay) and 178 samples from patients with HIV infection were tested the Elecsys anti-HCV Ⅱ assay and two comparator assays, Architect anti-HCV and Vitros anti-HCV assay. Confirmatory test was performed using recombinant immunoblot assay (RIBA) 3.0 or HCV RNA tests. Moreover, 203 samples with different HCV genotypes were assessed using the Elecsys anti-HCV Ⅱ assay to test its genotype inclusivity.Results The Elecsys anti-HCV Ⅱ assay detected HCV seroconversion 714 days earlier than the Architect anti-HCV and Vitros anti-HCV assay. It had 100% sensitivity and superior specificity in screening clinical routine samples. For the routine samples with positive anti-HCV by all the three screening assays, the S/Co values obtained using Elecsys anti-HCV Ⅱ did not correlate with those obtained Architect anti-HCV (P=0.13) Vitros anti-HCV (P=0.22) the S/Co values obtained correlated very well with a Pearson correlation coefficient of 0.97(P<0.01).Totally 73 preselected samples with low positive anti-HCV Results remained anti-HCV positive when retested the Vitros anti-HCV assay, among which only 18 samples tested positive using Elecsys anti-HCV Ⅱ and 36 samples tested positive using the Architect anti-HCV assay. The Elecsys anti-HCV Ⅱ assay significantly distinguished the 73 anti-HCV borderline Results ; 55 negative samples tested using Elecsys anti-HCV Ⅱ had S/Co ratios 0.0380.13, while 18 positive samples had S/Co ratios 13.58135.6, respectively.Only one sample with an S/Co ratio of 13.58 by Elecsys anti-HCV Ⅱ was confirmed as RIBA indeterminate, while the other 17 samples with S/Co ≥20.0 were all RIBA positive. There were 161 out of 178 samples from HIV infected patients tested anti-HCV positive while 14 samples tested negative using all the three screening.The remaining three samples generated discordant Results among the anti-HCV screening assays. The Elecsys anti-HCV Ⅱ assay, the Architect anti-HCV and the Vitros anti-HCV assay detected 97.6% (122/125) anti-HCV-positive samples from HIV-infected patients with HCV viremia. Using the Elecsys anti-HCV Ⅱ assay, however, the anti-HCV levels in the genotype 3b samples were slightly underestimated.ConclusionsThe Elecsys anti-HCV Ⅱ can further shorten the HCV seroconversion window due to its superior sensitivity. It is sensitive and specific enough for screening HCV infection in clinical routine samples as well.The Elecsys anti-HCV Ⅱ assay can be used together with either the Architect anti-HCV or the Vitros anti-HCV assay to improve the specificity in detecting samples with borderline positive anti-HCV S/Co ratios; this strategy will avoid unnecessary medical visits and psychological harm patients with a borderline positive anti-HCV result. The Elecsys anti-HCV Ⅱ assay is also suitable for testing samples from the immunocompromised patients, due to satisfactory sensitivity. Nevertheless, further investigation of its subtype inclusivity in a larger sample number might be warranted.
[1]Tang H, Grisé H. Cellular and molecular biology of HCV infection and hepatitis [J]. Clin Sci,2009,117(2):49-65. [2]Simmonds P, Bukh J, Combet C,et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology,2005,42(4):962-973. [3]Lauer GM, Walker BD.Hepatitis C virus infection[J].N Engl J Med,2001,345(1):41-52. [4]Di Bisceglie AM. Natural history of hepatitis C:its impact on clinical management[J]. Hepatology,2000,31(4):1014-1018. [5]Wei L, Wang QX, Xu XY,et al. 12-25-year follow-up of hepatitis C virus infection in a rural area of Hebei province,China[J]. J Peking Univ Health Sci,2002,34(5):574-578. [6]Kamili S, Drobeniuc J, Araujo AC,et al. Laboratory diagnostics for hepatitis C virus infection[J]. Clin Infect Dis,2012,55 (Suppl. 1):S43-48. [7]Donahue JG, Muñoz A, Ness PM,et al. The declining risk of post-transfusion hepatitis C virus infection[J]. N Engl J Med,1992,327(6):369-373. [8]Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors[J]. Transfusion,2005,45(2):254-264. [9]Couroucé AM, Le Marrec N, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period[J]. Transfusion,2000,40(10):1198-1202. [10]Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis[J]. N Engl J Med,1989,321(22):1494-1500. [11]Van der Poel CL, Cuypers HT, Reesink HW, et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay[J]. Lancet,1991,337(8737):317-319. [12]Dufour DR, Talastas M, Fernandez MD,et al. Chemiluminescence assay improves specificity of hepatitis C antibody detection[J]. Clin Chem,2003,49 (6 Pt 1):940-944. [13]Berger A, Rabenau H, Allwinn R,et al. Evaluation of the new ARCHITECT anti-HCV screening test under routine laboratory conditions[J]. J Clin Virol,2008,43(2):158-161. [14]Park Y, Seok Y, Choi J,et al. Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories[J]. Clin Biochem,2012,45(1-2):175-177. [15]Kim S, Kim JH, Yoon S,et al. Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection[J]. J Clin Microbiol,2008,46(12):3919-3923. [16]Alborino F, Burighel A, Tiller FW, et al. Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity[J]. Med Microbiol Immunol,2011,200(2):77-83. [17]Wei L, Lopez-Talavera JC, Rao HY, et al. Prevalence of HCV viral and host IL28B genotypes in China[J]. Hepatology,2011,54(Suppl 1):563A-564A. [18]Lu L, Nakano T, Li C, Fu Y,et al. Hepatitis C virus complete genome sequences identified from China representing subtypes 6k and 6n and a novel, as yet unassigned subtype within genotype 6[J]. J Gen Virol,2006,87(Pt 3):629-634. [19]Couroucé AM, Le Marrec N, Girault A,et al. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis:comparison of second- and third-generation anti-HCV assays[J]. Transfusion,1994,34(9):790-795. [20]Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus[J]. MMWR Recomm Rep,2003,52(RR-3):1-16. [21]Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians[J]. MMWR Morb Mortal Wkly Rep,2013,62(18):362-365. [22]Contreras AM, Tornero-Romo CM, Toribio JG, et al. Very low hepatitis C antibody levels predict false-positive results and avoid supplemental testing[J]. Transfusion,2008,48(12):2540-2548. [23]何云,赵清霞,任英杰等.128例经血感染HIV患者合并HCV和HBV感染状况[J].中国医学科学院学报,2006,28(5):662-664. [24]Sherman KE, Rouster SD, Chung RT,et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group[J]. Clin Infect Dis,2002,34(6):831-837. [25]Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms[J]. Clin Infect Dis,2012,55 (Suppl 1):S33-42. [26]Thio CL, Nolt KR, Astemborski J,et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals[J]. J Clin Microbiol,2000,38(2):575-577. [27]Myrmel H, Navaratnam V, AsjØ B. Detection of antibodies to hepatitis C virus: false-negative results in an automated chemiluminescent microparticle immunoassay (ARCHITECT Anti-HCV) compared to a microparticle enzyme immunoassay (AxSYM HCV Version 3.0) [J]. J Clin Virol,2005,34(3):211-215. [28]Echevarría JM, Avellón A, Jonas G,et al. Sensitivity of a modified version of the ARCHITECT Anti-HCV test in detecting samples with immunoblot-confirmed, low-level antibody to hepatitis C virus[J]. J Clin Virol,2006,35(4):368-372. [29]Pawlotsky JM, Roudot-Thoraval F, Pellet C, et al. Influence of hepatitis C virus (HCV) genotypes on HCV recombinant immunoblot assay patterns[J]. J Clin Microbiol,1995,33(5):1357-1359.
2013, Vol. 1 
